Biogen Idec
Biogen ventures into ophthalmology with $1-bn AGTC tie-up
04 July 2015
Biogen Idec to pay Elan Corp $3.25 bn plus for full rights of multiple sclerosis drug Tysabri
06 February 2013
Biogen assumes full development responsibilities for hemophilia therapy
18 February 2010
Facet Biotech spurns Biogenís buyout bid
09 September 2009
Biogen in talks to acquire Acorda for multiple sclerosis pill
25 February 2009
Biogen Idec shareholders reject Icahn's nominees to the board, reiterates support for management
21 June 2008
Biogen Idec up for sale after Icahn offer
13 October 2007
Nicholas Piramal enters into alliance with Biogen Idec, USA
02 December 2003
 search domain-b